Growth hormone response to a growth hormone-releasing hormone stimulation test in a population-based study following cranial irradiation of childhood brain tumors.
Children with brain tumors are at high risk of developing growth hormone deficiency (GHD) after cranial irradiation (CI) if the hypothalamus/pituitary (HP) axis falls within the fields of irradiation. The biological effective dose (BED) of irradiation to the HP region was determined, since BED gives a means of expressing the biological effect of various irradiation treatment schedules in a uniform way. Hypothalamic versus pituitary damage as cause of GHD was distinguished in 62 patients by comparing the growth hormone (GH) peak response to an insulin tolerance test (ITT)/arginine stimulation test and the GH response to a growth hormone-releasing hormone (GHRH) stimulation test. Peak GH response to a GHRH test was significantly higher (median 7.3 mU/l; range: 0.5--79.0 mU/l) than that of an ITT/arginine test (median 4.7 mU/l; range: 0.01--75.0 mU/l) (p = 0.017). Peak GH after a GHRH test was significantly inversely correlated to follow-up time (r(s) = -0.46, p < 0.0001) and to BED (R(s) = -0.28, p = 0.03), and both were found to be of significance in a multivariante regression analysis. We speculate that a significant number of patients developed hypothalamic radiation-induced damage to the GHRH secreting neurons, and secondary to this the pituitary gland developed decreased responsiveness to GHRH following CI in childhood.
Department of Growth and Reproduction, Juliane Marie Centre, National University Hospital, Rigshospitalet, Copenhagen, Denmark. rho4642@rh.dk
M
M
Schmiegelow
S
S
Lassen
H S
HS
Poulsen
U
U
Feldt-Rasmussen
K
K
Schmiegelow
H
H
Hertz
J
J
Müller
D000293:Adolescent; D001120:Arginine; D001921:Brain / Q000528:radiation effects*; D001932:Brain Neoplasms / Q000532:radiotherapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D013007:Growth Hormone-Releasing Hormone; D019382:Human Growth Hormone / Q000172:deficiency / Q000378:metabolism*; D006801:Humans; D007031:Hypothalamus / Q000528:radiation effects; D007223:Infant; D008297:Male; D010902:Pituitary Gland / Q000528:radiation effects; D011832:Radiation Injuries / Q000378:metabolism; D012062:Relative Biological Effectiveness; D013997:Time Factors
D019382:Human Growth Hormone; D013007:Growth Hormone-Releasing Hormone; D001120:Arginine